207804-90-8

Basic information

• Product Name: 5-trifluoromethyl-2-(1,3-dimethoxy-1,3-dioxopropan-2-yl)benzoic acid
• Synonyms: 5-trifluoromethyl-2-(1,3-dimethoxy-1,3-dioxopropan-2-yl)benzoic acid
• CAS NO: 207804-90-8
• Molecular Weight: 320.222
• Mol File: 207804-90-8.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: 5-trifluoromethyl-2-(1,3-dimethoxy-1,3-dioxopropan-2-yl)benzoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 5-trifluoromethyl-2-(1,3-dimethoxy-1,3-dioxopropan-2-yl)benzoic acid(207804-90-8)
• EPA Substance Registry System: 5-trifluoromethyl-2-(1,3-dimethoxy-1,3-dioxopropan-2-yl)benzoic acid(207804-90-8)

Safety Data

• Hazardous Substances Data: 207804-90-8(Hazardous Substances Data)

Upstream product

• 1483-56-3 2-bromo-5-(trifluoromethyl)benzoic acid 
• 108-59-8 malonic acid dimethyl ester 
• 657-06-7 2-chloro-5-trifluoromethylbenzoic acid 

Downstream Products

• 1609575-81-6 methyl 5-trifluoromethyl-2-(1,3-dimethoxy-1,3-dioxopropan-2-yl)benzoate 
• 1609576-14-8 N-(4-fluorobenzyl)-2-hydroxy-7-trifluoromethyl-1,3-dioxo-1,2,3,4-tetrahydroisoquinoline-4-carboxamide 
• 1609575-94-1 N-(4-fluorobenzyl)-2-(benzyloxy)-7-trifluoromethyl-1,3-dioxo-1,2,3,4-tetrahydroisoquinoline-4-carboxamide 
• 1609575-89-4 methyl 2-(benzyloxy)-7-trifluoromethyl-1,3-dioxo-1,2,3,4-tetrahydroisoquinoline-4-carboxylate 
• 1609575-84-9 methyl 2-{1-[(benzyloxy)amino]-3-methoxy-1,3-dioxopropan-2-yl}-5-trifluoromethylbenzoate 
• 207804-91-9 2-(carboxymethyl)-5-(trifluoromethyl)benzoic acid 
• 207804-93-1 2-[2-(hydroxymethyl)-4-(trifluoromethyl)phenyl]ethanol 
• 199678-32-5 7-(trifluoromethyl)-1,2,3,4-tetrahydroisoquinoline 

Relevant articles and documents

Investigation of a novel series of 2-hydroxyisoquinoline-1,3(2 H,4 H)-diones as human immunodeficiency virus type 1 integrase inhibitors

We report herein further insight into the biological activities displayed by a series of 2-hydroxyisoquinoline-1,3(2H,4H)-diones (HIDs). Substitution of the N-hydroxyimide two-metal binding pharmacophore at position 4 by carboxamido side chains was previously shown by us to be fruitful for this scaffold, since strong human immunodeficiency virus type 1 integrase (HIV-1 IN) inhibitors in the low nanomolar range associated with low micromolar anti-HIV activities were obtained. We investigated the influence of substitution at position 7 on biological activity. Introduction of electron-withdrawing functional groups such as the nitro moiety at position 7 led to a noticeable improvement of antiviral activity, down to low nanomolar anti-HIV potencies, with advantageous therapeutic indexes going close to those of the clinically used raltegravir and retained potencies against a panel of IN mutants.